Abstract: Objective To analyze and evaluate the current market competition and developments of new anti-tumor drugs in Nanjing, and recommend countermeasures to enhance the competitiveness of China's pharmaceutical industry. Methods Based on the statistics of the consumption of innovative anti-tumor drugs used in 35 secondary and tertiary hospitals in Nanjing between 2016 and 2019, the types, varieties, sales amount, market share of innovative anti-tumor drugs and the sales distribution of medicines produced by domestic or overseas manufacturers were analyzed. Results The sales amount of new anti-tumor drugs increased at an annual average rate of 41.27%. Cytotoxic drugs held almost 60% of the market share of innovative anti-tumor drugs. Among molecular targeted drugs, monoclonal antibodies and multi-target tyrosine kinase inhibitors were growing rapidly. New anti-tumor drugs accounted for about 20% of the total sales amount, and home-made new anti-tumor drugs accounted for about 60%. Conclusion The sales amount of innovative anti-tumor drugs in the terminal market in Nanjing is trending up. Targeted drugs have a large market space and tend to be used in combination with cytotoxic drugs. Compared with import enterprises, state-owned enterprises need to improve their ability to make innovations. enterprises, state-owned enterprises need to improve their ability to make innovations.

Key words: anti-tumor innovative drugs, sales amount, market competition, trend analysis